TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01154387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOL101
Description: Potential Therapeutic Dose (PTD)-A (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOL101
Description: Potential Therapeutic Dose (PTD)-B (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: IV methylprednisolone prior to first 3 doses of study drug; oral prednisone tapered to 5-10 mg over 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: IV methylprednisolone prior to first 3 doses of study drug; oral prednisone tapered to 5-10 mg over 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: IV methylprednisolone prior to first 3 doses of study drug; oral prednisone tapered to 5-10 mg over 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Oral administration started by 6 days post-transplantation and continued for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral administration started by 6 days post-transplantation and continued for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral administration started by 6 days post-transplantation and continued for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Description: Oral administration started by Day 1 post-transplantation and continued for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: Oral administration started by Day 1 post-transplantation and continued for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: Oral administration started by Day 1 post-transplantation and continued for 6 months
Study: NCT04320056

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard administration of oxygen flow
Description: The investigator recommended SpO2 target of 90-94%. The investigator will recommend that low/high SpO2 alarms be set at 88% and 96% if continuous oximetry is used.~In this group the SpO2 was recorded any time with FreeO2 device - recording mode

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated oxygen administration - FreeO2
Description: In this group, oxygen administration will be delivered with FreeO2 (automated oxygen titration) with SpO2 target set at 92% (to maintain oxygenation in the recommended SpO2 target: 90-94%)
Study: NCT00566553

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape Seed Extract
Description: 200 mg dose daily for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape Seed Extract
Description: 400 mg dose daily for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape Seed Extract
Description: 600 mg dose daily for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape Seed Extract
Description: 800 mg dose daily for 12 weeks.
Study: NCT04084405

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation
Description: The experimental group receives inspiratory muscle training and aerobic exercise. The Active Comparator group received only aerobic exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: The experimental group receives inspiratory muscle training and aerobic exercise. The Active Comparator group received only aerobic exercise.
Study: NCT04018157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine and dexmedetomidine and propofol and 0.9%saline
Description: patients will receive single intravenous bolus of combination from ketamine 0.5mg/kg and dexmedetomidine 1ug/kg in one syringe diluted in 10 ml 0.9% saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine and dexmedetomidine and propofol and 0.9%saline
Description: patients will receive single intravenous bolus of combination from ketamine 0.5mg/kg and dexmedetomidine 1ug/kg in one syringe diluted in 10 ml 0.9% saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine and dexmedetomidine and propofol and 0.9%saline
Description: patients will receive single intravenous bolus of combination from ketamine 0.5mg/kg and dexmedetomidine 1ug/kg in one syringe diluted in 10 ml 0.9% saline.
Study: NCT04030949

Intervention type: OTHER
Intervention: No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants
Description: No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants

Intervention type: OTHER
Intervention: No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants
Description: No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants

Intervention type: OTHER
Intervention: No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants
Description: No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants
Study: NCT03432767

Intervention type: DEVICE
Intervention: Non-invasive hemoglobin monitor
Study: NCT02279563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelastine HCl and Fluticasone Propionate Nasal Spray, 137 µg/50 µg per spray
Description: During the placebo lead-in period, the placebo nasal spray was administered via nasal inhalation with one spray in each nostril twice daily for 7days.~During the randomized treatment period, the investigational products (experimental, active comparator and placebo nasal spray) were administered via nasal inhalation with one spray in each nostril twice daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dymista™ Nasal Spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03143413

Intervention type: OTHER
Intervention: Ultrasonography
Description: Patient will be enrolled in the rheumatology department of University hospital of Clermont-Ferrand (France).~Salivary glands ultrasonography will be performed on all patients enrolled by the same expert and blinded to the diagnosis of the patient. Echostructure of the two salivary glands will be graded 0 to 4 and the size calculated.

Intervention type: OTHER
Intervention: Ultrasonography
Description: Patient will be enrolled in the rheumatology department of University hospital of Clermont-Ferrand (France).~Salivary glands ultrasonography will be performed on all patients enrolled by the same expert and blinded to the diagnosis of the patient. Echostructure of the two salivary glands will be graded 0 to 4 and the size calculated.

Intervention type: OTHER
Intervention: Ultrasonography
Description: Patient will be enrolled in the rheumatology department of University hospital of Clermont-Ferrand (France).~Salivary glands ultrasonography will be performed on all patients enrolled by the same expert and blinded to the diagnosis of the patient. Echostructure of the two salivary glands will be graded 0 to 4 and the size calculated.
Study: NCT04394286

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SHP648
Description: Participants will receive a single IV infusion of SHP648 in Cohort 1, 2, 3 on Day 0.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SHP648
Description: Participants will receive a single IV infusion of SHP648 in Cohort 1, 2, 3 on Day 0.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SHP648
Description: Participants will receive a single IV infusion of SHP648 in Cohort 1, 2, 3 on Day 0.
Study: NCT04390191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: CPAP at fixed pressure (8-10cm H20) for 72 hours continuously (except for daily activities such as eating, personal activities and breaks for ambulation etc).
Study: NCT01500161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan 3.2 mg/kg/day intravenously on days -7, -6, -5 and -4(for non-NHL patients patients who get Clofarabine regimen)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine intravenously 40 mg/m2/day on days -7, -6, -5, -4 and -3(for non-NHL patients patients who get Busulfan regimen)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/kg/day intravenously on days -7, -6, -5, -4 and -3 (for non-NHL patients who receive Melphalan containing regimen)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan intravenously 140 mg/m2/day on day -3 (only for non-NHL patients who receive Fludarabine OR for all NHL regimens)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: BCNU(Carmustine)300 mg/m2 intravenously on day -7 (for NHL patients only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 300 mg/m2/day intravenously on days -6, -5, -4 and -3 (for NHL patients only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: ARA-C(Cytarabine) 100 mg/m2/day on days -6, -5, -4 and -3 (for NHL patients only)
Study: NCT03365492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioFreedom™ BA9™ drug-coated stent
Description: Drug-coated stent for coronary arteries
Study: NCT02321878

Intervention type: DRUG
Intervention: liraglutide
Description: Liraglutide (Victoza®) will be prescribed by the physician under normal clinical practice conditions.~No treatment given.
Study: NCT03800329

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Snap40 Monitor
Description: Non-invasive, wearable armband device used to measure change in systolic blood pressure, respiratory rate, heart rate, body temperature, movement, and oxyhemoglobin saturation and streams this information to a cloud-based storage system. Patients will complete a questionnaire.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Monitor
Description: Patients will be discharged in the ordinary manner, without the Snap40 monitor. Patients will complete a questionnaire.
Study: NCT01867437

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile solution (vehicle) for subcutaneous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RM-493
Description: Sterile solution (2mg/ml) for subcutaneous infusion
Study: NCT03349580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The training group
Description: The training group performed rehabilitation program twice per week over 9 weeks. The group commenced rehabilitation 3 weeks after the surgery. During the phase one training (week 1 to week 5), the isometric exercises were preformed on the trunk extension, flexion and lateral flexion muscles. During the phase 2 (week 6 to week 9), the exercises were performed on the strength machines and duration of the exercises were maintained and prolonged to 30 seconds. The leg adduction and hip extension exercises were added. The patients were instructed to perform abdominal bracing (IAP) and maintain the neutral position of their lumbar spine before and during the exercises.
Study: NCT04011319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group culture
Description: Four embryos were cultured in the same droplet by a special dish.
Study: NCT02865265

Intervention type: PROCEDURE
Intervention: Pecs II and parasternal blocks
Description: Pecs II block was performed at the level of the fourth rib in the fascial plane between the minor pectoral and serratus anterior muscles, and 20 ml of 0.5% levobupivacaine solution were injected.~An ultrasound-guided ipsilateral parasternal block was performed via two separate injections of 4 ml of 0.375% levobupivacaine at the level of the 2nd and 4th intercostal space underneath the external intercostal membrane between the major pectoral and intercostal muscles close to the surface of the 2nd and 4th rib.
Study: NCT01176240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: 100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02053519

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Vigantol Oil (Vitamin D3)
Description: Vitamin D Oral oil 100.000iu in 5 mls

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mygliol Oil
Description: Matched placebo comparator
Study: NCT04191213

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acacia Senegal extract
Description: Oral Digestion of Gum Arabic to be consumed early morning in daily basis for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pectin
Description: Oral Digestion of Pectin to be consumed early morning in daily basis for 12 weeks
Study: NCT02274415

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with the combined vaccine (Prevenar13 ®)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with the polysaccharide vaccine (Pneumo 23 ®)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination with the polysaccharide vaccine (Pneumo 23 ®)
Study: NCT02205164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron + Aprepitant
Description: Aloxi 0.25mg Emend 125/80/80 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron
Description: Aloxi 0.25mg
Study: NCT02580838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: Early OnabotulinumtoxinA group will receive OnabotulinumtoxinA injection when their spasticity develop, late OnabotulinumtoxinA group will have injection at 6 months after emergence of spasticity, the third group will not have OnabotulinumtoxinA intervention.
Study: NCT00915759

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProKera
Description: ProKera placed in non-dominant eye after PRK
Study: NCT02580838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: Early OnabotulinumtoxinA group will receive OnabotulinumtoxinA injection when their spasticity develop, late OnabotulinumtoxinA group will have injection at 6 months after emergence of spasticity, the third group will not have OnabotulinumtoxinA intervention.
Study: NCT01969513

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PROCEDURE: EPLEY MANOEUVRE
Description: The procedure involves a series of four movements of the head and body from sitting to lying, rolling over and back to sitting.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: PROCEDURE: SHAM MANOEUVRE
Description: Placebo manoeuvre is performed with the patient lying down over the affected side for 5 minutes as it is described in similar studies.
Study: NCT01041404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Initial loading dose 8 mg/kg i.v. infusion on Day 1 of cycle, followed by 6 mg/kg i.v. infusion every 3 weeks until disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: 800 mg/m2 i.v. infusion on Days 1 through 5 of cycle every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 800 mg/m2 i.v. infusion on Days 1 through 5 of cycle every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 80 mg/m2 i.v. infusion on Day 1 of cycle every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m2 i.v. infusion on Day 1 of cycle every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m2 p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2 p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles
Study: NCT02500277

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoprobe pleural biopsy first
Description: Four pleural biopsy specimens will be obtained using the flexible cryoprobe (ERBOCRYOCA, ERBE, Tubingen, Germany; outer diameter 1.9 mm, length 900 mm) followed by 6-10 pleural biopsy specimens obtained using the flexible thoracoscopic forceps (FB-55CR, Olympus Medical Systems, 2 mm diameter).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible forceps biopsy first
Description: Six to ten pleural biopsy specimens will be obtained using the flexible thoracoscopic forceps (FB-55CR, Olympus Medical Systems, 2 mm diameter) followed by four pleural biopsy specimens obtained using the flexible cryoprobe (ERBOCRYOCA, ERBE, Tubingen, Germany; outer diameter 1.9 mm, length 900 mm)
Study: NCT03497611

Intervention type: PROCEDURE
Intervention: transcatheter valve implantation
Description: aortic transcatheter valve implantation using Edwards SAPIEN 3 valve
Study: NCT00567957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: 1 microg/kg iv bolus before induction followed by 0.5 microg/kg/min infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: same volume iv bolus before induction followed by same volume infusion
Study: NCT00748865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane Ultra Lubricant Eye Drops
Description: Systane Ultra Lubricant Eye Drops 1 drop each eye one time

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systane Lubricant Eye Drops
Description: Systane Lubricant Eye Drops 1 drop each eye one time
Study: NCT02439736

Intervention type: OTHER
Intervention: Blood draw within 12 hours of head injury
Study: NCT01251822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG 3350 plus electrolytes
Description: Each sachet of PEG 3350 is dissolved in 125 mL of water. Patients receive two sachets of PEG 3350 plus electrolytes followed by two placebo tablets for the first 14 days, after which dosage adjustment is permitted, according to effect. Each patient is treated for 28 days in total.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: Patients less than 65 years of age receive a solution containing two sachets of reconstituted placebo followed by two prucalopride 1 mg tablets for 28 days.~Patients more than 65 years of age receive a solution containing two sachets of reconstituted placebo followed by one prucalopride 1 mg tablet and one placebo tablet for 28 days.
Study: NCT02098005

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care evidence-based physiotherapy
Description: Arm 1 (i.e., the control group) will be subjected to a control intervention, including back/neck school and general exercises. 3 sessions of education (session 1: group session; session 2: online module; session 3: individual session) will be given by a physiotherapist, followed by 15 sessions of traditional physiotherapy and general exercises. The 18 sessions will be spread over a period of 3 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modern neuroscience approach
Description: Arm 2 (i.e., the experimental group) will receive pain neuroscience education (3 sessions of education), followed by 15 sessions of cognition-targeted motor control training (15 sessions). The 18 sessions will be spread over a period of 3 months.
Study: NCT04253808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted, high-fat diet
Description: Diet composition was \~45% fats, \~30% carbohydrates, and \~25% proteins. Calorie needs were provided according to what the Bioelectrical Impedance (BIA) device gave as required to maintain bodyweight.~Sources of macronutrients:~* Carbohydrates: from whole grains, dairy products, legumes, fruits, and vegetables.~* Fats: from mono- and polyunsaturated fatty acids, including medium- and long-chain fatty acids.~* Proteins: plant-based proteins and lean animal-based proteins. All meals were provided to the participants throughout the study period and the diet was provided orally unless the patient was on a feeding tube or a feeding tube is ordered by a physician during the study period. Diet texture was according to patients chewing and swallowing abilities. If the patient is on a feeding tube or intake is insufficient, a formula with similar macronutrient composition + a protein supplement was provided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular composition diet
Description: The regular composition diet contained approximately 50-52% carbohydrates, 30% fats, and 18-20% proteins
Study: NCT00415545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fluid Watchers LITE Educational Intervention
Description: Patients in Fluid Watchers LITE will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written material, a diary, a scale and a telephone follow-up to answer any questions they might have about the educational session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fluid Watchers PLUS Educational Intervention
Description: Patients in Fluid Watchers PLUS will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written materials, a diary, a scale, an audio tape of the session and telephone followup. Participants in the PLUS program will receive additional counseling, audio tapes, and follow-up telephone calls on a biweekly basis, as compared to participants in the LITE program.
Study: NCT02776852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number: SR15-43-Y65-158)